Repligen clears antitrust review for BioLife deal, but vote still looms

One regulatory hurdle is cleared, but the acquisition is not closed. The HSR waiting period expired at 11:59 p.m. Eastern Time on September 3, removing the required antitrust waiting period. 〔0〕 The merger still depends on other customary conditions, including BioLife stockholder approval. (Other Events) 〔1〕

The deal economics are unchanged. Repligen continues to offer BioLife holders $11.25 in cash plus 0.1442 Repligen shares per BioLife share, terms already announced with the July 21 merger agreement. (Merger consideration)

Versus the standing expectation, this is an in-line procedural update. The acquisition itself was already disclosed, and the filing adds no revised price, closing date, synergy target, or financial outlook. Clearing HSR modestly reduces execution risk, but the key remaining catalyst is the BioLife stockholder meeting scheduled for October 5, 2026. (Other Events) 〔2〕